Aware Super Pty Ltd as trustee of Aware Super Acquires 11,017 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• Aware Super increased its Vertex Pharmaceuticals stake by 121.9% in the third quarter, adding 11,017 shares to reach 20,055 shares valued at about $10.5 million.
• Vertex reported third-quarter revenue of $3.44 billion, up 11.8% year over year and above estimates, but adjusted earnings of $4.76 per share missed expectations of $4.82.
• The company raised its 2026 sales outlook and highlighted potential growth from newer medicines and povetacicept; analysts’ consensus rating is “Moderate Buy,” with an average price target of $596.11.

Aware Super Pty Ltd as trustee of Aware Super boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 121.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 20,055 shares of the pharmaceutical company's stock after acquiring an additional 11,017 shares during the quarter. Aware Super Pty Ltd as trustee of Aware Super's holdings in Vertex Pharmaceuticals were worth $10,485,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bangor Savings Bank increased its position in shares of Vertex Pharmaceuticals by 0.4% during the 2nd quarter. Bangor Savings Bank now owns 4,470 shares of the pharmaceutical company's stock worth $2,220,000 after purchasing an additional 20 shares during the last quarter. Trust Point Inc. raised its holdings in Vertex Pharmaceuticals by 2.7% in the 2nd quarter. Trust Point Inc. now owns 793 shares of the pharmaceutical company's stock valued at $394,000 after buying an additional 21 shares during the period. Integrated Advisors Network LLC lifted its position in Vertex Pharmaceuticals by 1.4% in the third quarter. Integrated Advisors Network LLC now owns 1,625 shares of the pharmaceutical company's stock valued at $850,000 after buying an additional 22 shares during the last quarter. Glenview Trust Co lifted its position in Vertex Pharmaceuticals by 0.3% in the third quarter. Glenview Trust Co now owns 6,773 shares of the pharmaceutical company's stock valued at $3,541,000 after buying an additional 22 shares during the last quarter. Finally, Cannell & Spears LLC lifted its position in Vertex Pharmaceuticals by 1.2% in the first quarter. Cannell & Spears LLC now owns 1,983 shares of the pharmaceutical company's stock valued at $885,000 after buying an additional 23 shares during the last quarter. Hedge funds and other institutional investors own 90.96% of the company's stock.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue rose 11.8% year over year to $3.44 billion, topping estimates, supported by Vertex’s cystic-fibrosis franchise and growth from newer medicines including CASGEVY and JOURNAVX. The company also raised its 2026 sales outlook. Read More.
• Positive Sentiment: Management expressed confidence in the anticipated launch of povetacicept for IgA nephropathy ahead of an FDA decision, an important potential growth driver beyond cystic fibrosis. Several analysts also raised their price targets after the results. Read More. · Read More.
• Negative Sentiment: Adjusted earnings of $4.76 per share fell short of estimates. Acquisition and launch-related spending weighed on profit, while sales of the newer pain drug JOURNAVX were described as light—dampening the market’s reaction to the revenue beat. Read More.

Wall Street Analysts Forecast Growth

VRTX has been the subject of a number of recent analyst reports. Canaccord Genuity Group lifted their price target on shares of Vertex Pharmaceuticals from $436.00 to $442.00 and gave the company a "hold" rating in a research report on Tuesday, August 4th. Wells Fargo & Company upped their price objective on shares of Vertex Pharmaceuticals from $550.00 to $650.00 and gave the stock an "overweight" rating in a report on Tuesday. Barclays increased their price objective on shares of Vertex Pharmaceuticals from $615.00 to $617.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 5th. Cantor Fitzgerald increased their price objective on shares of Vertex Pharmaceuticals from $595.00 to $619.00 and gave the stock an "overweight" rating in a research report on Tuesday. Finally, Truist Financial lifted their target price on shares of Vertex Pharmaceuticals from $560.00 to $565.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $596.11.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX opened at $530.76 on Wednesday. The company's 50-day simple moving average is $522.98 and its 200-day simple moving average is $480.37. Vertex Pharmaceuticals Incorporated has a 1 year low of $403.16 and a 1 year high of $568.67. The stock has a market capitalization of $134.71 billion, a PE ratio of 34.15, a P/E/G ratio of 2.65 and a beta of 0.28.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing analysts' consensus estimates of $4.82 by ($0.06). Vertex Pharmaceuticals had a net margin of 30.70% and a return on equity of 22.40%. The business had revenue of $3.44 billion during the quarter, compared to analyst estimates of $3.42 billion. During the same quarter last year, the firm posted $4.80 EPS. The company's revenue for the quarter was up 11.8% on a year-over-year basis. On average, sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 16.74 earnings per share for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.